Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol PACB
- Company Pacific Biosciences of California, Inc.
- Price $1.85
- Changes Percentage -7.96
- Change -0.16
- Day Low $1.8
- Day High $2.08
- Year High $7.5
- Year Low $1.16
- Market Cap $506,648,400
- Price Avg 50 EMA (D) $2.02
- Price Avg 200 EMA (D) $1.89
- Exchange NASDAQ
- Volume 12,236,660
- Average Volume 9,627,193
- Open $1.93
- Previous Close $2.01
- EPS -1.46
- PE -1.27
- Earnings Announcement 2025-02-13 10:59:00
- Shares Outstanding $273,864,000
Company brief: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB )
- Healthcare
- Medical - Devices
- Mr. Christian O. Henry M.B.A.
- https://www.pacb.com
- US
- N/A
- 10-27-2010
- US69404D1081
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
PACB Corporation News
PacBio Announces Preliminary Fourth Quarter and Full Year Revenue
globenewswire.com -- Commenced shipment of the Vega ™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers...
PacBio Stock May Gain Following the Collaborated Launch of GutID
zacks.com -- PACB and Intus Bio collaborate to launch GutID, the first commercial human gut health test....
PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics
zacks.com -- PacBio delivers the first Vega systems to Berry Genomics to develop and optimize its targeted assays to support screening programs in China and other markets....
PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing
globenewswire.com -- MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discover...